BMC Infectious Diseases最新文献

{"title":"Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).","authors":"Ivan Gentile, Agnese Giaccone, Maria Michela Scirocco, Francesco Di Brizzi, Federica Cuccurullo, Maria Silvitelli, Luigi Ametrano, Francesco Antimo Alfè, Daria Pietroluongo, Irene Irace, Mariarosaria Chiariello, Noemi De Felice, Simone Severino, Giulio Viceconte, Nicola Schiano Moriello, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Riccardo Scotto","doi":"10.1186/s12879-025-11043-w","DOIUrl":"https://doi.org/10.1186/s12879-025-11043-w","url":null,"abstract":"","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"633"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical pharmacists' interventions about drug therapy problems and its acceptability by prescribers among pediatric hospitalized patients with infectious diseases in resource-limited settings.","authors":"Tilaye Arega Moges, Samuel Berihun Dagnew, Sisay Sitotaw Anberbr, Getachew Yitayew Tarekegn, Taklo Simeneh Yazie, Getu Tesfaw Addis, Teklie Mengie Ayele, Kidist Hunegn Setargew, Fisseha Nigussie Dagnew","doi":"10.1186/s12879-025-11044-9","DOIUrl":"https://doi.org/10.1186/s12879-025-11044-9","url":null,"abstract":"<p><strong>Background: </strong>Infectious disease continues to be a major cause of death among pediatrics. Drug therapy problem (DTP) is a significant public health challenge that is highly prevalent in pediatrics, and it has an impact on the effectiveness and safety of drug therapy to a greater extent than in adults. Thus, this study aimed to determine the magnitude of DTPs, types and acceptability of pharmaceutical interventions by prescribers and its associated factors among hospitalized pediatric patients with infectious diseases at pediatric wards of Public comprehensive specialized hospitals (PCSHs).</p><p><strong>Methods: </strong>This multicenter crosssectional study was conducted among pediatric patients with infectious disease admitted to PCSH pediatric wards from December 01, 2023, to February 30, 2024. Cipolle's and Strand's DTP classification methods were used for the identification of DTPs. Pharmaceutical interventions and their acceptance rate by prescribers were classified according to the Pharmaceutical Care Network Europe (PCNE) 2019. Data was entered and analyzed into SPSS version 27. To identify predictors of DTP occurrence, multivariable logistic regression analysis was used. A pvalue of less than 0.05 was considered statistically significant.</p><p><strong>Results: </strong>A total of 389 pediatric patients were involved in the current study, selected from an initial sample size of 405, resulting in a response rate of 96.05%. The overall prevalence of DTPs was 56.56% which occurred in 220 pediatric hospitalized patients with infectious disease. The most commonly encountered type of pharmaceutical intervention provided was adjusting the dose of medication (25.2%), followed by patient education/counseling/adherence (23.2%), and discontinuation of medications (20.54%). The acceptance level of interventions by prescribers was high (84.0%). Medication non-compliance (43.6%), unnecessary drug therapy (16.0%), and dose too high (12.0%) were common types of DTPs. Patients with the prolonged hospital stay (6-10 days) [AOR = 2.02, 95%CI: 1.33-7.80] and more than ten days in hospital [AOR = 2.89, 95%CI: 1.90-11.23]; patients with high number of medications (≥ 5) [AOR = 4.60, 95%CI: 1.89-8.82]; those who paid for their medications [AOR = 2.19, 95%CI: 1.18, 3.31], and patients with comorbidity [AOR = 3.90, 95% CI: 1.56-8.15] were the predictors of the occurrence of DTPs.</p><p><strong>Conclusion: </strong>This study finding revealed that the magnitude of DTPs was high in pediatric inpatients with infectious diseases at PCSHs. The presence of comorbidity, source of medication fee, polypharmacy, and prolonged hospital stays were factors associated with the occurrence of DTPs. The acceptance rate of interventions by the prescribers was high. Clinical pharmacists' involvement in direct patient care responsibility astutely reduces drug therapy problems and hence increases patient safety.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"629"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPACO+: a mixed methods protocol to assessing the effectiveness of an educative intervention in patients with Long Covid.","authors":"Odette Linda Kamdem, Caroline Dupre, Valdez Heugno, Amandine Baudot, Estelle Essangui, Marie Blanquet, Nina Guercon, Marie Fanget, Sasha Bayet, Marie Pierre Vericel, Pauline Oustric, Yves Mbama Biloa, Elie Shikitele Lola, Mabrouk Nekaa, Mario Debellis, François Stierlam, Ronelle Fabiola Mbia, Olivier Tatsilong, Peguy Assomo Ndemba, Williams Bell Ngan, Valérie Ndobo, Clarisse Ayina Ayina, Jerson Mekoulou, Marie Solange Ndom Ebongue, Thomas Celarier, Louise Ruiz, Veronique Regnier, Claude Bika, Françoise Ngo Sack, Judith Laure Ngondi, Nathalie Barth, Samuel Honore Mandengue, Frederic Roche, Elisabeth Botelho-Nevers, Carole Else Eboumbou Moukoko, Céline Nguefeu Nkenfou, David Hupin, Bienvenu Bongue, Jessica Guyot","doi":"10.1186/s12879-025-10992-6","DOIUrl":"https://doi.org/10.1186/s12879-025-10992-6","url":null,"abstract":"<p><strong>Background: </strong>The management of many chronic diseases requires a multidisciplinary and holistic approach. Long Covid is a recent, poorly understood disease with several symptoms. Most recommendations suggest a multidisciplinary approach. While there are a few programs aimed to the management of Long Covid, to our knowledge very few were assessed. The SPACO + study therefore aims to evaluate an innovative program which combines the methods used in therapeutic education and in personalized multifactorial intervention for management of Long Covid. Here, we present the protocol of our study, which aims to evaluate the effectiveness of an educational intervention in terms of changes in quality of life at 6 months in comparison with standard clinical practice in patients suffering from Long Covid.</p><p><strong>Methods: </strong>To achieve our objectives, we have planned to carry out a prospective, multicentre, two-arm randomized controlled trial with a convergent parallel mixed methods design. Two countries are involved in this study: France and Cameroon. The study concerns patients aged 18 and over, who have been infected with Covid-19. They must also be diagnosed as having Long Covid in accordance with the WHO definition. The number of subjects required for the study is 400 individuals. Participants will be randomly assigned to either the intervention or control group using a dynamic randomization process to ensure balanced group characteristics. The SPACO + program is an educative intervention with individual follow-up by a nurse dedicated to the program. The SPACO + program offers five workshops, two of which are compulsories. Patients take part in the other workshops according to their needs. The program includes an 8 - 10 weeks intervention period. Each session lasts two hours and includes breaks (pacing). The main outcome measure will be quality of life, evaluated through the SF-36. Primary and secondary outcomes, with few exceptions, are assessed before the intervention (\"T0\"), at 8 weeks (\"T1\" corresponding to the end of SPACO + program's session period) and then 3 months later (\"T2\").</p><p><strong>Discussion: </strong>If the SPACO + program is effective and accepted by professionals and patients, it could be disseminated in other regions to assess its transferability. The medico-economic evaluation will also make it possible to assess the benefits provided.</p><p><strong>Trial registration: </strong>This trial is registered under the number NCT05787366 (March 24, 2023). Protocol Version N°3.0 (May 31, 2024).</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"623"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between early enteral nutrition and 28-Day mortality in mechanically ventilated patients with sepsis: a retrospective analysis of the MIMIC-IV database.","authors":"Fuchao Xu, Geng Lu, Hao Sun, Jun Wang","doi":"10.1186/s12879-025-10912-8","DOIUrl":"https://doi.org/10.1186/s12879-025-10912-8","url":null,"abstract":"<p><strong>Background: </strong>The optimal timing of enteral nutrition for critically ill septic patients in the intensive care unit (ICU) who require invasive mechanical ventilation has not been determined, and the influence of early enteral nutrition on clinical outcomes is unclear.</p><p><strong>Methods: </strong>This retrospective observational study utilized data from the Medical Information Mart for Intensive Care IV 2.2 (MIMIC-IV 2.2) database to investigate patients with sepsis who needed invasive mechanical ventilation post-ICU admission. Patients who had enteral nutrition (EN) initiated within 72 h of ICU were categorized into the early enteral nutrition (EEN) group, while those who began enteral nutrition after 72 h were placed in the delayed enteral nutrition (DEN) group. Propensity score matching analysis was performed to compare outcomes between these two groups, with the primary outcome being 28-day mortality.</p><p><strong>Results: </strong>The final analysis included 2293 patients, 1546 (67.4%) of whom received enteral nutrition within 72 h of invasive mechanical ventilation. The overall 28-day mortality rate was 31.0%. After propensity score matching employing the proximity matching method, Cox survival analysis revealed that early enteral nutrition was associated with increased 28-day mortality in septic patients on invasive mechanical ventilation (hazard ratio(HR) 1.440, 95% CI 1.179-1.760; p < 0.001). The sensitivity and robustness of the evaluation results under different models, including optimal matching (adjusted odds ratio (aOR) 1.52, 95% CI 1.21-1.92, p < 0.001), inverse probability of treatment weighting (aOR 1.27, 95% CI 1.02-1.58, p = 0.034), and logistic regression analysis (aOR 1.48, 95% CI 1.18-1.84, p = 0.001), confirmed the association between early enteral nutrition and increased 28-day mortality in mechanically ventilated septic patients.</p><p><strong>Conclusions: </strong>Compared to delayed enteral nutrition, early enteral nutrition is associated with higher 28-day mortality in septic patients on invasive mechanical ventilation. Randomized controlled trials are warranted to validate these findings.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"628"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of clinical antimicrobial-resistant Enterobacterales in Togo over three decades: a systematic review and meta-analysis, with recommendations and alternative solutions.","authors":"Komla Mawunyo Dossouvi, Fábio Parra Sellera, Ephraim Ehidiamen Ibadin, Ishola Ayinla Cherif Adeshola, Kosi Agbeko Djanta, Chancelle Afi Guido Amesse, Yaovi Senam Egoh, Ayawovi Selom Ametepe, Kpalma Duga Bakpatina-Batako, Amr El Kelish, Sika Dossim","doi":"10.1186/s12879-025-11035-w","DOIUrl":"https://doi.org/10.1186/s12879-025-11035-w","url":null,"abstract":"<p><strong>Background: </strong>According to the World Health Organization (WHO), surveillance programs have become essential at national, regional, and global levels to adjust empirical treatments and target interventions to prevent and control the emergence of antimicrobial resistance (AMR). Therefore, this study aimed to conduct the first systematic review and meta-analysis of clinical Enterobacterales resistance to 11 representative antimicrobials from the WHO AWaRe (Access, Watch, Reserve) list, and to provide recommendations to tackle AMR more efficiently in Togo.</p><p><strong>Methods: </strong>The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (The PRISMA 2020) were used to conduct this study and the protocol was registered with PROSPERO (CRD42024606897). Keywords were used to conduct a systematic literature review of electronic databases. Data analysis was conducted using Stata software version 17.0.</p><p><strong>Results: </strong>Twenty research articles reporting 9,327 clinical Enterobacterales isolates obtained from 1991 to 2020 were included in this review and were mainly Escherichia coli (6,639; 71.2%), and Klebsiella spp. (2,542; 27.3%), mainly isolated from urine (14 studies; 70%), and pus/wounds (12; 60%). The pooled Enterobacterales resistance rates ranged from 1% (95% CI: 0, 2) imipenem, 3% (95% CI: 1, 5) amikacin, 4% (95% CI: 2, 7) fosfomycin, 50% (95% CI: 40, 60) chloramphenicol, 55% (95% CI: 45, 64) gentamicin, 68% (95% CI: 59, 76) ciprofloxacin, 73% (95% CI: 66, 80) amoxicillin/clavulanic acid (AMC), 79% (95% CI: 71, 86) third-generation cephalosporins (3GC), to 90% (95% CI: 86, 93) sulfamethoxazole/trimethoprim (SXT). The most significant upward trend over 30 years was reported for SXT (R² = 73.24%, p < 0.001), ciprofloxacin (R² = 61.44%, p < 0.001), and 3GC (R² = 18.49%, p < 0.001). Klebsiella spp. strains were significantly more resistant to chloramphenicol (p = 0.03) than E. coli isolates, whereas E. coli isolates were significantly more resistant to amikacin (p = 0.04) than Klebsiella spp. isolates.</p><p><strong>Conclusion: </strong>This study revealed high first-line AMR rates with drastic upward trends in clinical Enterobacterales isolated in Togo over the past 30 years. Thus, the adjustment of empirical antimicrobial treatments in Togo becomes crucial. Moreover, the implementation of prevention policies, whole-genome sequencing approaches, and the promotion of antibiotic stewardship must be enhanced. Finally, alternative therapeutic approaches, such as phytotherapy and phage therapy, were discussed.</p><p><strong>Clinical trial: </strong>Not applicable.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"632"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden and predictors of hospital-acquired infection in intensive care units across Sub-Sahara Africa: systematic review and metanalysis.","authors":"Ousman Adal, Yeshimebet Tamir Tsehay, Birhanu Ayenew, Teshager Woldegiyorgis Abate, Gebrehiwot Berie Mekonnen, Sileshi Mulatu, Sosina Tamre Mamo, Temesgen Ayenew, Mengistu Abebe Messelu, Asnake Gashaw Belayneh","doi":"10.1186/s12879-025-11038-7","DOIUrl":"https://doi.org/10.1186/s12879-025-11038-7","url":null,"abstract":"<p><strong>Background: </strong>Hospital-acquired infection (HAI) refers to an infection that occurs during hospitalization and typically manifests 48 h after admission. Evidence suggests that the prevalence of HAIs in Sub-Saharan Africa (SSA) is significantly higher compared to other regions. These infections remain a major concern in low-income countries, contributing to elevated morbidity and mortality rates. This study aimed to assess the burden and identify predictors of HAIs in intensive care units (ICUs) across SSA.</p><p><strong>Methods: </strong>This review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched PubMed, Scopus, Embase, Web of Science, Africa Index Medicus, ScienceDirect, HINARI, and Google Scholar to identify relevant studies published in English. This systematic review encompasses 44 articles published between 2003 and 2024, with the majority (22 articles) published recently between 2020 and 2024. The actual database search was conducted between January 1, 2025, and February 1, 2025. Articles irrelevant to this study's objectives, those without abstracts or full texts, unpublished reports, editorials, studies that did not clearly define outcomes, and studies written in languages other than English were excluded. The analysis was conducted using Stata version 17. The protocol was registered with PROSPERO under the registration number CRD 63,194,923,892. Quality assessment was performed using the Newcastle-Ottawa Scale, and data extraction followed the Joanna Briggs Institute methodology.</p><p><strong>Results: </strong>A total of 44 primary samples were included in this meta-analysis. Using the random effect DerSimonian model, we showed that the pooled prevalence of hospital-acquired infections (HAIs) in intensive care units was 28.22% (95% CI: 23.61-32.81). Determinants of HAIs in the intensive care units included neonatal or advanced age (> 50 years), intubation, trauma, surgery, presence of comorbidities, catheterization, prolonged hospital stay, and HIV-positive status.</p><p><strong>Conclusion and recommendations: </strong>Individuals in extreme age groups, those with chronic diseases or immunocompromised conditions, and patients with specific risk factors (e.g., catheterization, prolonged hospitalization) were more prone to HAIs. Strengthening the quality of care and implementing effective infection control measures are recommended to reduce the burden of healthcare-associated infections (HAIs) in sub-Saharan Africa.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"634"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of clinical and microbiological characteristics of invasive Klebsiella pneumoniae liver abscess syndrome.","authors":"Li Gu, Yue Wang, Han Wang, Dong Xu","doi":"10.1186/s12879-025-10981-9","DOIUrl":"https://doi.org/10.1186/s12879-025-10981-9","url":null,"abstract":"<p><strong>Background: </strong>Invasive Klebsiella pneumoniae liver abscess syndrome (IKPLAS) is emerging as a new disease worldwide, threatening human health. This study aimed to investigate the clinical and microbiological features of IKPLAS in order to detect this syndrome early and select antibiotics appropriately.</p><p><strong>Methods: </strong>Medical data from patients in Tongji Hospital, China, diagnosed with Klebsiella pneumoniae liver abscess (KPLA) between 2015 and 2023 was collected and analyzed retrospectively.</p><p><strong>Results: </strong>The study included 208 patients with KPLA, 41 with IKPLAS, and 167 with non-IKPLAS (NIKPLAS). Multivariate logistic regression analysis demonstrated that symptoms in other organ systems (including ocular, pulmonary, and neurological symptoms) (p = 0.001) and a sequential organ failure assessment (SOFA) score ≥ 4 within 48 h of admission (P = 0.002) were significant risk factors for IKPLAS. Patients with IKPLAS had a higher risk of developing multiple organ dysfunction (MODS), and a PCT ≥ 10 ng/mL was identified as an independent risk factor for MODS (p = 0.01). IKPLAS was associated with significantly prolonged hospital stays and unfavorable outcomes (all p < 0.05). There were no significant differences in microbiological characteristics between IKPLAS and NIKPLAS, including the antimicrobial susceptibility pattern and resistance profile of Klebsiella pneumoniae (KP) (all p > 0.05). In this study, KP isolates were susceptible to most antibiotics, with low rates of drug resistance. Specifically, a total of five carbapenem-resistant strains (2.6%) and seven multidrug-resistant strains (3.6%) were detected, all of which were derived from the NIKPLAS group.</p><p><strong>Conclusions: </strong>Symptoms in other organ systems and the SOFA score ≥ 4 within 48 h of admission were significant predictors for IKPLAS. This study elucidated the antimicrobial susceptibility profile of liver abscess-associated KP strains, providing a reference for the early initiation of rational and effective antimicrobial therapy in patients with KPLA.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"626"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143951952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacts of the COVID-19 pandemic on sepsis incidence, etiology and hospitalization costs in France: a retrospective observational study.","authors":"Marie Al Rahmoun, Alexandre Sabaté-Elabbadi, Didier Guillemot, Christian Brun-Buisson, Laurence Watier","doi":"10.1186/s12879-025-11000-7","DOIUrl":"https://doi.org/10.1186/s12879-025-11000-7","url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a serious medical condition that causes long-term morbidity and high mortality, annually affecting millions of people worldwide. The COVID-19 pandemic may have impacted its burden. This study aimed to estimate the impact of the COVID-19 pandemic on sepsis incidence, etiology and associated hospitalization costs in metropolitan France.</p><p><strong>Methods: </strong>This retrospective observational study used data drawn from a cohort of hospitalized sepsis patients in France's national healthcare database. Sepsis was identified through both explicit International Classification of Diseases 10th revision (ICD-10) codes (E-sepsis) and implicit codes (I-sepsis). Participants included all patients aged 15 years or older hospitalized with E-sepsis or I-sepsis in metropolitan France between January 1, 2018, and December 31, 2022. Patient and hospital stay characteristics were described by sepsis type (E-sepsis, I-sepsis) and overall. The distribution of sepsis etiology was estimated for each year. Annual incidence rates were estimated overall and by sepsis type and etiology. Total and median per-stay hospitalization costs were calculated.</p><p><strong>Results: </strong>The total age- and sex-standardized sepsis incidence rate per 100,000 increased slightly from 2018 (446, 95% CI 444.2 to 447.7) to 2020 (457, 95% CI 455.1 to 458.6) and then decreased in 2022 (382, 95% CI 380.2 to 383.7) (p <.0001). Incidence rates decreased for both E-sepsis and bacterial sepsis during the pandemic period, whereas I-sepsis incidence increased in 2020 and 2021, associated with a marked increase in viral sepsis and co-infections (p <.0001 for E- and I-sepsis). Viral sepsis represented about 10% of all sepsis cases during the pandemic, but only about 1% prior to the pandemic. Total sepsis-associated hospitalization costs and extra medication costs increased during the pandemic. Characteristics of patients and their hospital stays were overall stable over the five-year study period.</p><p><strong>Conclusions: </strong>The COVID-19 pandemic led to a higher burden of sepsis in French hospitals and an increase in hospital stay costs. Critically, our study highlights the need for introducing more explicit viral sepsis codes within the ICD classification system and for achieving a consensus on its definition in order to robustly estimate sepsis incidence.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"627"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognostic factors of pulmonary tuberculosis with interstitial changes.","authors":"Junjie Ning, Shenglin Chi, Yuanwei Zhang, Lina Qiao","doi":"10.1186/s12879-025-10970-y","DOIUrl":"https://doi.org/10.1186/s12879-025-10970-y","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary tuberculosis (PTB) remains a significant global public health challenge, particularly in its manifestation as interstitial lung disease. This form complicates clinical presentation, increasing the difficulty of diagnosis and treatment. However, studies on PTB with interstitial changes are relatively scarce, and their clinical significance and prognostic value have not been fully explored. The objective of the present study was to identify the key factors affecting clinical characteristics and prognosis in these patients.</p><p><strong>Methods: </strong>This retrospective study analyzed data from patients diagnosed with PTB with Interstitial Changes at Zigong First People's Hospital in Sichuan Province between January 2014 and January 2024. Sixteen patients meeting strict inclusion and exclusion criteria were enrolled. Clinical characteristics and key prognostic factors were identified using descriptive statistics and random forest analysis, with partial dependence plots generated to illustrate the independent contributions of each variable to adverse outcomes.</p><p><strong>Results: </strong>Among the 16 patients studied, 75.0% were male and 25.0% were female. The average number of pathogen species detected was 1.56 ± 0.73, and 31.3% of patients presented with fever symptoms at admission. Hospital stay durations ranged from 8 to 67 days, with a mean of 22.00 ± 16.02 days. Regarding drug resistance, 25.0% of patients exhibited rifampicin resistance, and approximately 31.2% had underlying diseases. Ultimately, 11 patients (68.8%) recovered, while 5 (31.2%) died. The random forest model identified age, rifampicin resistance, and the number of pathogen species as the main determinants of prognosis. Advanced age and drug resistance were significantly associated with a higher risk of death, and patients infected with multiple pathogens experienced worse outcomes.</p><p><strong>Conclusions: </strong>This study enhances our understanding of the clinical characteristics and prognosis of tuberculosis patients presenting with interstitial lung disease, particularly identifying advanced age, rifampicin resistance, and a higher number of pathogen species as key prognostic factors. These findings provide valuable insights for the development of personalized treatment strategies and precision medicine approaches for this patient group.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"624"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12039248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in chest imaging between Omicron and non-Omicron coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.","authors":"Yingying Han, Zhijia Wang, Xingzhao Li, Zhuan Zhong","doi":"10.1186/s12879-025-11032-z","DOIUrl":"https://doi.org/10.1186/s12879-025-11032-z","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) have posed a great threat to human health. We carried out this systematic review and meta-analysis for two objectives. First, to evaluate the differences in lung infection between the Omicron variants and the non-Omicron strains by chest computed tomography (CT); second, to evaluate the differences in chest CT features between COVID-19 patients with the Omicron variants and those with non-Omicron strains in CT-positive cases.</p><p><strong>Methods: </strong>We searched PubMed, Embase, Web of Science and China National Knowledge Infrastructure for articles and performed a meta-analysis using Stata 14.0 with a random effects model.</p><p><strong>Results: </strong>Our study included a total of 8126 patients with COVID-19, 4113 with the Omicron variants, and 4013 with non-Omicron strains. Patients with the Omicron variants were less likely to be CT-positive (OR = 0.14, 95% CI: 0.08-0.25), and further analysis among CT-positive patients was performed. Compared with the CT images of patients with non-Omicron strains, those of patients with the Omicron variants showed atypical pulmonary features (OR = 4.02, 95% CI: 2.31-6.98). Moreover, patients with the Omicron variants typically had lesions that were mainly located in the center of the lung (OR = 4.51, 95% CI: 1.38-14.76) and in a single lobe (OR = 1.72, 95% CI: 1.10-2.70). The patients with the Omicron variants were less likely to have lesions in both lungs (OR = 0.33, 95% CI: 0.15-0.69), more likely to have bronchial wall thickening (OR = 1.99, 95% CI: 1.05-3.77) and less likely to have the crazy-paving pattern (OR = 0.51, 95% CI: 0.33-0.81), linear opacity (OR = 0.26, 95% CI: 0.12-0.60), and vascular enlargement (OR = 0.54, 95% CI: 0.35-0.84).</p><p><strong>Conclusions: </strong>Through meta-analysis, which yields the highest level of evidence for evidence-based medicine, we further confirmed that there were significant differences in the distribution and manifestations of lesions between patients with non-Omicron strains and those with the Omicron variants on chest CT. The variation in SARS-CoV-2 has never stopped. Our findings are useful for the diagnosis and treatment of new SARS-CoV-2 variants that may appear in the future and provide a basis for public health decision-making.</p><p><strong>Prospero registration number: </strong>CRD42024581869.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"631"},"PeriodicalIF":3.4,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}